Intradermal Tozinameran for Patients With Immune-mediated Dermatologic Diseases

Summary

This is a randomised controlled trial conducted to prove that the immunological performance of intradermal tozinameran (i.e., Pfizer-BioNTech COVID-19 vaccine) is no worse than the standard intramuscular route in patients with immune-mediated dermatologic diseases. The side effects profile and disease activity post-vaccination will also be assessed.

Timeline

Start

2022-06-15

Primary completion

2023-03-20

Completion

2023-05-01

Drugs

Indications